Kenneth W. Tuell, RPh, BCGP

Articles

Real-World Outcomes Among Patients With Early Rapidly Progressive Rheumatoid Arthritis

September 24, 2019

This study suggests that lower healthcare resource use and achieving low disease activity are associated with first-line abatacept compared with a first-line tumor necrosis factor-α inhibitor for patients with early rapidly progressive rheumatoid arthritis.